Brigitte Lina Kieffer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Brigitte Lina Kieffer has a total of 482 co-authors. Here are the top co-authors by number of shared publications:
- Emmanuel Darcq
INSERM UMR-S1329, Strasbourg Translational Neuroscience & Psychiatry, University of Strasbourg
28 shared publications Emmanuel Darcq
University of Strasbourg, French Institute of Health and Medical Research UMR-S 1329, Strasbourg Translational Neuroscience and Psychiatry, Centre de Recherche en Biomedicine de Strasbourg, Strasbourg, France; Douglas Research Center, Department of Psychiatry, McGill University, Montréal, Quebec, Canada
9 shared publications- Laura-Adela Harsan
Department of Radiology, Medical Physics, Medical Center University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany
9 shared publications Sami Ben Hamida
INSERM UMR 1247 University of Picardie Jules Verne Amiens France
9 shared publications- Tanzil Mahmud Arefin
Department of Neuroscience, University of Rochester Medical Center, Rochester, New York, USA
6 shared publications Michael McNicholas
Douglas Mental Health University Institute, Montreal, Canada
5 shared publications
Latest Publications
- Open Access
- 19 June 2025
- Published by Wiley in Addiction Biology
- Vol. 30 (6) , e70058
The GPR88 Agonist RTI‐122 Reduces Alcohol‐Related Motivation and Consumption
GPR88, an orphan G protein‐coupled receptor primarily expressed in the striatum, has emerged as a potential target for treating alcohol use disorder (AUD) due to its role in modulating reward and motivational pathways. In this study, we investigated the effects of the GPR88 agonist RTI‐122 on alcohol intake and motivation to self‐administer alcohol under different conditions. In mice, RTI‐122 reduced alcohol consumption in a two‐bottle choice paradigm, which was prevented by Gpr88 knockout, confirming a GPR88‐specific effect on the attenuation of alcohol drinking. In rats, RTI‐122 dose‐dependently reduced operant alcohol self‐administration and decreased motivation to self‐administer alcohol in progressive ratio tasks, regardless of whether the alcohol was adulterated with quinine or not. Additionally, a high dose of RTI‐122 reduced yohimbine‐induced reinstatement. Importantly, RTI‐122 did not affect water intake in mice or sucrose self‐administration in rats, indicating receptor‐ and reward‐specific modulation of alcohol intake. These findings suggest that RTI‐122, through GPR88 agonism, effectively reduces alcohol consumption and motivation across various contexts, positioning it as a promising lead for the development of new AUD treatments.
- 19 June 2025
- Published by Wiley in Addiction Biology
- Vol. 30 (6) , e70058
Open AccessThe GPR88 Agonist RTI‐122 Reduces Alcohol‐Related Motivation and Consumption
GPR88, an orphan G protein‐coupled receptor primarily expressed in the striatum, has emerged as a potential target for treating alcohol use disorder (AUD) due to its role in modulating reward and motivational pathways. In this study, we investigated the effects of the GPR88 agonist RTI‐122 on alcohol intake and motivation to self‐administer alcohol under different conditions. In mice, RTI‐122 reduced alcohol consumption in a two‐bottle choice paradigm, which was prevented by Gpr88 knockout, confirming a GPR88‐specific effect on the attenuation of alcohol drinking. In rats, RTI‐122 dose‐dependently reduced operant alcohol self‐administration and decreased motivation to self‐administer alcohol in progressive ratio tasks, regardless of whether the alcohol was adulterated with quinine or not. Additionally, a high dose of RTI‐122 reduced yohimbine‐induced reinstatement. Importantly, RTI‐122 did not affect water intake in mice or sucrose self‐administration in rats, indicating receptor‐ and reward‐specific modulation of alcohol intake. These findings suggest that RTI‐122, through GPR88 agonism, effectively reduces alcohol consumption and motivation across various contexts, positioning it as a promising lead for the development of new AUD treatments.
- Top Cited PapersOpen Access
- 22 May 2024
- Published by Springer Nature in Nature
- Vol. 630 (8015) , 141-148
Distinct µ-opioid ensembles trigger positive and negative fentanyl reinforcement
Fentanyl is a powerful painkiller that elicits euphoria and positive reinforcement1. Fentanyl also leads to dependence, defined by the aversive withdrawal syndrome, which fuels negative reinforcement2,3 (that is, individuals retake the drug to avoid withdrawal). Positive and negative reinforcement maintain opioid consumption, which leads to addiction in one-fourth of users, the largest fraction for all addictive drugs4. Among the opioid receptors, µ-opioid receptors have a key role5, yet the induction loci of circuit adaptations that eventually lead to addiction remain unknown. Here we injected mice with fentanyl to acutely inhibit γ-aminobutyric acid-expressing neurons in the ventral tegmental area (VTA), causing disinhibition of dopamine neurons, which eventually increased dopamine in the nucleus accumbens. Knockdown of µ-opioid receptors in VTA abolished dopamine transients and positive reinforcement, but withdrawal remained unchanged. We identified neurons expressing µ-opioid receptors in the central amygdala (CeA) whose activity was enhanced during withdrawal. Knockdown of µ-opioid receptors in CeA eliminated aversive symptoms, suggesting that they mediate negative reinforcement. Thus, optogenetic stimulation caused place aversion, and mice readily learned to press a lever to pause optogenetic stimulation of CeA neurons that express µ-opioid receptors. Our study parses the neuronal populations that trigger positive and negative reinforcement in VTA and CeA, respectively. We lay out the circuit organization to develop interventions for reducing fentanyl addiction and facilitating rehabilitation.
- 22 May 2024
- Published by Springer Nature in Nature
- Vol. 630 (8015) , 141-148
Top Cited PapersOpen AccessDistinct µ-opioid ensembles trigger positive and negative fentanyl reinforcement
Fentanyl is a powerful painkiller that elicits euphoria and positive reinforcement1. Fentanyl also leads to dependence, defined by the aversive withdrawal syndrome, which fuels negative reinforcement2,3 (that is, individuals retake the drug to avoid withdrawal). Positive and negative reinforcement maintain opioid consumption, which leads to addiction in one-fourth of users, the largest fraction for all addictive drugs4. Among the opioid receptors, µ-opioid receptors have a key role5, yet the induction loci of circuit adaptations that eventually lead to addiction remain unknown. Here we injected mice with fentanyl to acutely inhibit γ-aminobutyric acid-expressing neurons in the ventral tegmental area (VTA), causing disinhibition of dopamine neurons, which eventually increased dopamine in the nucleus accumbens. Knockdown of µ-opioid receptors in VTA abolished dopamine transients and positive reinforcement, but withdrawal remained unchanged. We identified neurons expressing µ-opioid receptors in the central amygdala (CeA) whose activity was enhanced during withdrawal. Knockdown of µ-opioid receptors in CeA eliminated aversive symptoms, suggesting that they mediate negative reinforcement. Thus, optogenetic stimulation caused place aversion, and mice readily learned to press a lever to pause optogenetic stimulation of CeA neurons that express µ-opioid receptors. Our study parses the neuronal populations that trigger positive and negative reinforcement in VTA and CeA, respectively. We lay out the circuit organization to develop interventions for reducing fentanyl addiction and facilitating rehabilitation.
- Open Access
- 29 April 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-13
Model of negative affect induced by withdrawal from acute and chronic morphine administration in male mice
Opioid use disorder (OUD) is a chronic relapsing disorder that is a major burden for the lives of affected individuals, and society as a whole. Opioid withdrawal is characterized by strong physical symptoms, along with signs of negative affect. Negative affect due to opioid withdrawal is a major obstacle to recovery and relapse prevention. The mechanisms behind negative affect due to either spontaneous or antagonist-precipitated opioid withdrawal are not well known, and more animal models need be developed. Here, we present behavioral models of negative affect upon naloxone-precipitated morphine withdrawal in adult male mice. Social, anxiety, and despair-like deficits were investigated following naloxone administration in mice receiving morphine under three dosing regimens; acute, chronic constant dose and chronic escalating doses. Social behaviour in the three-chamber social preference test was decreased following withdrawal from chronic and escalating but not acute morphine. Anxiety-like behaviour in the open field was increased for all three treatments. Despair-like behaviour was increased following withdrawal from chronic and escalating but not acute morphine. Altogether, these animal models will contribute to study behavioural and neuronal circuitries involved in the several negative affective signs characterizing OUD.
- 29 April 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-13
Open AccessModel of negative affect induced by withdrawal from acute and chronic morphine administration in male mice
Opioid use disorder (OUD) is a chronic relapsing disorder that is a major burden for the lives of affected individuals, and society as a whole. Opioid withdrawal is characterized by strong physical symptoms, along with signs of negative affect. Negative affect due to opioid withdrawal is a major obstacle to recovery and relapse prevention. The mechanisms behind negative affect due to either spontaneous or antagonist-precipitated opioid withdrawal are not well known, and more animal models need be developed. Here, we present behavioral models of negative affect upon naloxone-precipitated morphine withdrawal in adult male mice. Social, anxiety, and despair-like deficits were investigated following naloxone administration in mice receiving morphine under three dosing regimens; acute, chronic constant dose and chronic escalating doses. Social behaviour in the three-chamber social preference test was decreased following withdrawal from chronic and escalating but not acute morphine. Anxiety-like behaviour in the open field was increased for all three treatments. Despair-like behaviour was increased following withdrawal from chronic and escalating but not acute morphine. Altogether, these animal models will contribute to study behavioural and neuronal circuitries involved in the several negative affective signs characterizing OUD.
- Open Access
- 16 March 2024
- Published by Springer Nature in Journal of Neural Transmission
- Vol. 131 (5) , 405-408
Neuroscience and addiction research: current advances and perspectives
- 16 March 2024
- Published by Springer Nature in Journal of Neural Transmission
- Vol. 131 (5) , 405-408
Open AccessNeuroscience and addiction research: current advances and perspectives
- 15 December 2023
- Published by Elsevier in Biological Psychiatry
- Vol. 96 (9) , 708-716
Chronic Morphine Leaves a Durable Fingerprint on Whole-Brain Functional Connectivity
- 15 December 2023
- Published by Elsevier in Biological Psychiatry
- Vol. 96 (9) , 708-716
Chronic Morphine Leaves a Durable Fingerprint on Whole-Brain Functional Connectivity
- 28 July 2023
- Published by Elsevier in Biological Psychiatry
- Vol. 95 (3) , 266-274
Manipulating ΔFOSB in D1-Type Medium Spiny Neurons of the Nucleus Accumbens Reshapes Whole-Brain Functional Connectivity
- 28 July 2023
- Published by Elsevier in Biological Psychiatry
- Vol. 95 (3) , 266-274
Manipulating ΔFOSB in D1-Type Medium Spiny Neurons of the Nucleus Accumbens Reshapes Whole-Brain Functional Connectivity
- 29 June 2023
- Published by Elsevier in Biological Psychiatry
- Vol. 94 (11) , 852-862
Mu Opioid Receptor–Positive Neurons in the Dorsal Raphe Nucleus Are Impaired by Morphine Abstinence
- 29 June 2023
- Published by Elsevier in Biological Psychiatry
- Vol. 94 (11) , 852-862
Mu Opioid Receptor–Positive Neurons in the Dorsal Raphe Nucleus Are Impaired by Morphine Abstinence
- 5 June 2023
- Published by Elsevier in Biological Psychiatry
- Vol. 94 (11) , 842-851
Mu Opioid Receptor–Expressing Neurons in the Dorsal Raphe Nucleus Are Involved in Reward Processing and Affective Behaviors
- 5 June 2023
- Published by Elsevier in Biological Psychiatry
- Vol. 94 (11) , 842-851
Mu Opioid Receptor–Expressing Neurons in the Dorsal Raphe Nucleus Are Involved in Reward Processing and Affective Behaviors
- Open Access
- 31 March 2023
- Published by Elsevier in Neuropharmacology
- Vol. 232, 109524
Advances in the characterization of negative affect caused by acute and protracted opioid withdrawal using animal models
- 31 March 2023
- Published by Elsevier in Neuropharmacology
- Vol. 232, 109524
Open AccessAdvances in the characterization of negative affect caused by acute and protracted opioid withdrawal using animal models
- 29 December 2022
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 80, 129120
Synthesis and pharmacological validation of a novel radioligand for the orphan GPR88 receptor
- 29 December 2022
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 80, 129120
Synthesis and pharmacological validation of a novel radioligand for the orphan GPR88 receptor